Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

Homecas57285-09-3

57285-09-3

57285-09-3 structural image
Product Name: HUMAN INHIBIN A
Formula: C10H14N5O7P
Inquiry

CHEMICAL AND PHYSICAL PROPERTIES

Physical Description White powder; [Sigma-Aldrich MSDS]
Color/Form Clear, colorless
Melting Point >100 °C
Other Experimental Properties Isoelectric point pH 10.5. Stable in neutral or acidic media at high temp. Irreversible changes in molecular structure occur in strongly alkaline media (pH >12). Partially and reversibly denatured on treatment with 8M urea. May be kept at room temp in physiological saline soln for >1 yr without detrimental effects.
Chemical Classes Other Uses -> Biochemical Research

SAFETY INFORMATION

Signal word Danger
Pictogram(s)
GHS08
Health Hazard
GHS08
GHS Hazard Statements H360:Reproductive toxicity
Precautionary Statement Codes P201:Obtain special instructions before use.
P308+P313:IF exposed or concerned: Get medical advice/attention.

COMPUTED DESCRIPTORS

Molecular Weight 6511 g/mol
XLogP3 -25.4
Hydrogen Bond Donor Count 93
Hydrogen Bond Acceptor Count 97
Rotatable Bond Count 111
Exact Mass 6510.0514478 g/mol
Monoisotopic Mass 6507.0413833 g/mol
Topological Polar Surface Area 2820 Ų
Heavy Atom Count 454
Formal Charge 0
Complexity 16700
Isotope Atom Count 0
Defined Atom Stereocenter Count 57
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
Covalently-Bonded Unit Count 1
Compound Is Canonicalized Yes

PRODUCT INTRODUCTION

description

Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death. The substance is consequently made available only for very restricted research use.